Drug updated on 10/18/2024
| Dosage Form | Capsule (oral; 100 mg) |
| Drug Class | CXC chemokine receptor 4 antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
Latest News
Summary
- This summary is based on the review of one randomized controlled trial(s). [1]
- Mavorixafor significantly increased the LS mean Time Above Absolute Neutrophil Count (TATANC) to 15.0 hours compared to 2.8 hours for placebo (P < .001).
- Mavorixafor significantly increased the LS mean Time Above Absolute Lymphocyte Count (TATALC) to 15.8 hours compared to 4.6 hours for placebo (P < .001).
- Mavorixafor significantly reduced the LS mean annualized infection rate to 1.7 compared to 4.2 for placebo (P = .007).
- No treatment-emergent adverse events (TEAEs) led to discontinuation, and no serious TEAEs related to the treatment were observed.
- Mavorixafor was generally well tolerated, with a favorable safety profile in individuals aged ≥12 years with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Xolremdi (mavorixafor) Prescribing Information. | 2024 | X4 Pharmaceuticals Inc., Boston, MA |
Randomized Controlled Trials
| Document Title | Sex Distribution | Year | Source |
|---|---|---|---|
| A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome | 31Subjects F: 58% M: 42% | 2024 | Blood |
Sex Distribution:
F:58%
M:42%
31Subjects
Year:
2024
Source:Blood